Drug Profile
Mazindol controlled release - NLS Pharmaceutics Ltd
Alternative Names: Mazindol extended release - NLS Pharmaceutics Ltd; NLS 0; NLS 1; NLS-10; NLS-13; NLS-2; Nolazol; QuilienceLatest Information Update: 04 Jul 2023
Price :
$50
*
At a glance
- Originator NLS Pharma Ltd
- Developer NLS Pharmaceutics Ltd
- Class 3-ring heterocyclic compounds; Anorectics; Behavioural disorder therapies; Drug withdrawal therapies; Imidazoles; Isoindoles; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Orexin receptor type 2 agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Attention-deficit hyperactivity disorder; Idiopathic hypersomnia; Narcolepsy
- No development reported Opioid-related disorders
Most Recent Events
- 04 Jul 2023 9393464- Trial FE updated for AMAZE program. Added KDM for trial protocol approval.
- 03 Jul 2023 NLS Pharmaceutics plans the phase III NLS-1031 trial, part of AMAZE program that includes two identical trials for Narcolepsy (PO, Extended release) in US in July 2023 (NCT05914194)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Opioid-related-disorders in Switzerland (PO, Controlled release)